Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Automated red blood cell exchange boosts quality of life for sickle cell patients

You live every day not knowing what's going to happen." Terumo BCT makes the Spectra Optia™ Apheresis System, a platform used to collect and remove sickled cells from the blood of patients with SCD. The company advocates globally for patients with...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

electrophysiological dysfunction of TDP-43 M337V mutated motor neurons, showcasing the potential for NUZ-001 to be a transformative treatment for ALS. Importantly, these findings reinforce the promising efficacy results seen in Neurizon's Phase 1...

International Conference on Neuroscience and Neurology 2024

Science: Advancements, Challenges, and Future Directions,” aiming to engage, empower, and develop new ideas in this platform for a better healthcare system. Attendees will have the unique opportunity to learn from leading experts in the field,...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

Axonal.AI today unveiled its groundbreaking platform, designed to significantly accelerate speed to market in the life sciences industry. At a time when rapid commercialization is more critical than ever, Axonal.AI's cutting-edge technology...

Orsini begins distribution of CASGEVY® (exagamglogene autotemcel), a gene-editing therapy

(SCD) with recurrent vaso-occlusive crises or (2) transfusion-dependent β-thalassemia (TDT). Read the Full Prescribing Information here. "With our Cell and Gene Therapy Center of Excellence established over seven years ago, Orsini is...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

frequent speaker and guest lecturer around the world. The privately-held company is based in Chicago, Illinois. For more information please visit www.ResQPharma.com.

Bracco Diagnostics Inc. reaches one million injections milestone with its MRI agent, VUEWAY® (gadopiclenol)

organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. For more information please visit, www.bracco.com

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

Chief Executive Officer of SystImmune, commented, "Our mission at SystImmune is to bring therapies that can provide transformative clinical benefit to patients. As BL-M17D1 is developed using our next generation linker and payload technology, the...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). For more information please visit, www.aadibio.com

Cure51 selects 10x Genomics Visium HD to drive its new drug discovery initiative

proprietary multi-omics database of exceptional cancer survivors. 10x Genomics' Visium HD assay, enables researchers to perform whole transcriptome spatial gene expression analysis at single cell-scale resolution. The assay will enable Cure51's...

GoodRx debuts a new e-commerce platform, starting with Opill®

GoodRx the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible...

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica's needle-free drug delivery system aims to be a urology treatment platform for...

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

elderly, is divided into two types: dry and wet. Often occurring in the late stages of AMD progression, GA is an advanced form of dry AMD that causes damage to retinal tissue, eventually leading to blindness. In the US alone, approximately 1.5...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com

2nd International Conference on Biotechnology and Bioengineering 2024

talents, and research in the realm of biotechnology. The Biotechnology Congress 2024 provides an exceptional platform for researchers, exhibitors, investigators, doctors, professors, scholars, delegates, and students to come together to explore,...

3rd BioPharma 2024

Get ready to connect, learn, and exchange ideas as we explore the cutting-edge strategies that optimize site performance and drive successful clinical trial.

Great Bay Bio launches its Intelligent Drug Development Ecosystem

future, Great Bay Bio will adhere to technological innovation and work with global partners to further promote the transformation and development of the biopharmaceutical industry, so that patients around the world can enjoy the benefits brought by...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

outcomes, and quality of life measures. The plan is to enroll fifty-six participants to allow an assessment of ATX-01's performance in this population. Dr. Judy Walker, Chief Medical Officer of ARTHEx, added, "The ArthemiR™ trial is designed to...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults. For more information please visit, www.claritypharmaceuticals.com